N-acetylcysteine, a novel treatment for Helicobacter pylori infection

Digestive Diseases and Sciences

Volumn 49, Issue 11-12, 2004, Pages 1853-1861

  Huynh, Hien Quoc ^a,c,d   Couper, Richard T L ^a,b   Tran, Cuong D ^a   Moore, Lynette ^a   Kelso, Richard ^a   Butler, Ross N ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Helicobacter pylori; Hydrophobicity; Mucus; N acetylcysteine; Treatment

Indexed keywords

ACETYLCYSTEINE; AGAR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL STRAIN; COLONY FORMING UNIT; CONTACT ANGLE; CONTROLLED STUDY; DILUTION; FEMALE; GASTRITIS; HELICOBACTER FELIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HYDROPHOBICITY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; DRUG RESISTANCE, BACTERIAL; EXPECTORANTS; FEMALE; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER FELIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HYDROPHOBICITY; MICE; MICE, INBRED C57BL; TIME FACTORS;

EID: 13644266906     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-004-9583-2     Document Type: Article

References (51)

1. Passaro DJ, Chosy EJ, Parsonnet J: Helicobacter pylori: Consensus and controversy. Clin Infect Dis 35:298-304, 2002
2. Nomura A, Stemmermann GN, Chyou PH, Perez-Perez GI, Blaser MJ: Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 120:977-981, 1994
3. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD: Helicobacter pylori infection and gastric lymphoma. N Engl J Med 330:1267-1271, 1994
4. Qasim A, O'Morain CA: Review article: Treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther 16 (Suppl 1):24-30, 2002
5. Mollison LC, Stingemore N, Wake RA, Cullen DJ, McGechie DB: Antibiotic resistance in Helicobacter pylori. Med J Aust 173:521-523, 2000
6. Scott D, Weeks D, Melchers K, Sachs G: The life and death of Helicobacter pylori. Gut 43 (Suppl 1):S56-S60, 1998
7. Jarosz M, Dzieniszewski J, Dabrowska-Ufniarz E, Wartanowicz M, Ziemlanski S, Reed PI: Effects of high dose vitamin C treatment on Helicobacter pylori infection and total vitamin C concentration in gastric juice. Eur J Cancer Prev 7:449-454, 1998
8. Goodman KJ, Correa P, Tengana Aux HJ, DeLany JP, Collazos T: Nutritional factors and Helicobacter pylori infection in Colombian children. J Pediatr Gastroenterol Nutr 25:507-515, 1997
9. Ziment I: Acetylcysteine: A drug that is much more than a mucokinetic. Biomed Pharmacother 42:513-519, 1988
10. Misawa M and Imamura N: [In vitro evaluation of mucolytic activities of some expectorants using porcine gastric mucin]. Nippon Yakurigaku Zasshi 92:263-270, 1988
11. Parry MF, Neu HC: Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro. J Clin Microbiol 5:58-61, 1977
12. Riise GC, Qvarfordt I, Larsson S, Eliasson V, Andersson BA: Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro. Respiration 67:552-558, 2000
13. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR: The effect of oral N-acetylcysteine in chronic bronchitis: A quantitative systematic review. Eur Respir J 16:253-262, 2000
14. Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJ, Williams R: Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: A prospective controlled trial. BMJ 303:1026-1029, 1991; Ben-Ari Z, Vaknin H, Tur-Kaspa R: N-Acetylcysteine in acute hepatic failure (non-paracetamol-induced) . Hepatogastroenterology 47:786-789, 2000
15. Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJ, Williams R: Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: A prospective controlled trial. BMJ 303:1026-1029, 1991; Ben-Ari Z, Vaknin H, Tur-Kaspa R: N-Acetylcysteine in acute hepatic failure (non-paracetamol-induced) . Hepatogastroenterology 47:786-789, 2000
16. Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, Dixon MF: A standardized mouse model of Helicobacter pylori infection: Introducing the Sydney stain. Gastroenterology 112:1386-1397, 1997
17. Lee A, Fox JG, Otto G, Murphy J: A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology 99:1315-1323, 1990
18. Reina J, Alomar P: [Biochemical, physiological, and enzymatic study of 78 strains of Helicobacter (Campylobacter) pylori isolated from gastroduodenal biopsies]. Enferm Infecc Microbiol Clin 8:153-156, 1990
19. Court M, Robinson PA, Dixon MF, Crabtree JE: Gastric Helicobacter species infection in murine and gerbil models: Comparative analysis of effects of H. pylori and H. felis on gastric epithelial cell proliferation. J Infect Dis 186:1348-1352, 2002
20. Stolte M, Meining A: The updated Sydney system: classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol 15:591-598, 2001
21. Spychal RT, Marrero JM, Saverymuttu SH, Northfield TC: Measurement of the surface hydrophobicity of human gastrointestinal mucosa. Gastroenterology 97:104-111, 1989
22. Hackelsberger A, Platzer U, Nilius M, Schultze V, Gunther T, Dominguez-Munoz JE, Malfertheiner P: Age and Helicobacter pylori decrease gastric mucosal surface hydrophobicity independently. Gut 43:465-469, 1998; Day AS, Jones NL, Policova Z, Jennings HA, Yau EK, Shannon P, Neumann AW and Sherman PM: Characterization of virulence factors of mouse-adapted Helicobacter pylori strain SS1 and effects on gastric hydrophobicity. Dig Dis Sci 46:1943-1951, 2001
23. Hackelsberger A, Platzer U, Nilius M, Schultze V, Gunther T, Dominguez-Munoz JE, Malfertheiner P: Age and Helicobacter pylori decrease gastric mucosal surface hydrophobicity independently. Gut 43:465-469, 1998; Day AS, Jones NL, Policova Z, Jennings HA, Yau EK, Shannon P, Neumann AW and Sherman PM: Characterization of virulence factors of mouse-adapted Helicobacter pylori strain SS1 and effects on gastric hydrophobicity. Dig Dis Sci 46:1943-1951, 2001
24. Zala G, Flury R, Wust J, Meyenberger C, Ammann R, Wirth HP: Omeprazole/amoxicillin: Improved eradication of Helicobacter pylori in smokers because of N-acetylcysteine. Schweiz Med Wochenschr 124:1391-1397, 1994
25. Olofsson AC, Hermansson M, Elwing H: N-Acetyl-L-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces. Appl Environ Microbiol 69:4814-4822, 2003
26. Perez-Giraldo C, Rodriguez-Benito A, Moran FJ, Hurtado C, Blanco MT, Gomez-Garcia AC: Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J Antimicrob Chemother 39:643-646, 1997
27. Zheng CH, Ahmed K, Rikitomi N, Martinez G, Nagatake T: The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol 43:107-113, 1999
28. An YH, Friedman RJ: Concise review of mechanisms of bacterial adhesion to biomaterial surfaces. J Biomed Mater Res 43:338-348, 1998
29. Stark RM, Gerwig GJ, Pitman RS, Potts LF, Williams NA, Greenman J, Weinzweig IP, Hirst TR, Millar MR: Biofilm formation by Helicobacter pylori. Lett Appl Microbiol 28:121-126, 1999
30. Hogan DL, Ainsworth MA, Isenberg JI: Review article: Gastroduodenal bicarbonate secretion. Aliment Pharmacol Ther 8:475-488, 1994
31. Shimizu T, Akamatsu T, Sugiyama A, Ota H, Katsuyama T: Helicobacter pylori and the surface mucous gel layer of the human stomach. Helicobacter 1:207-218, 1996
32. Slomiany BL, Liau YH, Lopez RA, Piotrowski J, Czajkowski A, Slomiany A: Effect of Helicobacter pylori lipopolysaccharide on the synthesis of sulfated gastric mucin. Biochem Int 27:687-697, 1992
33. Byrd JC, Yunker CK, Xu QS, Sternberg LR, Bresalier RS: Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterology 118:1072-1079, 2000
34. Dial EJ, Hall LR, Serna H, Romero JJ, Fox JG, Lichtenberger LM: Antibiotic properties of bovine lactoferrin on Helicobacter pylori. Dig Dis Sci 43:2750-2756, 1998
35. Drouin E: Helicobacter pylori: Novel therapies. Can J Gastroenterol 13:581-583, 1999
36. Bell AE, Sellers LA, Allen A, Cunliffe WJ, Morris ER, Ross-Murphy SB: Properties of gastric and duodenal mucus: Effect of proteolysis, disulfide reduction, bile, acid, ethanol, and hypertonicity on mucus gel structure. Gastroenterology 88:269-280, 1985
37. Goggin PM, Marrero JM, Spychal RT, Jackson PA, Corbishley CM, Northfield TC: Surface hydrophobicity of gastric mucosa in Helicobacter pylori infection: Effect of clearance and eradication. Gastroenterology 103:1486-1490, 1992
38. Gotoh A, Akamatsu T, Shimizu T, Shimodaira K, Kaneko T, Kiyosawa K, Ishida K, Ikeno T, Sugiyama A, Kawakami Y, Ota H, Katsuyama T: Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter 7:183-191, 2002
39. Phull PS, Green CI, Jacyna MR: A radical view of the stomach: The role of oxygen-derived free radicals and anti-oxidants in gastroduodenal disease. Eur J Gastroenterol Hepatol 7:265-274, 1995
40. Li CQ, Pignatelli B, Ohshima H: Increased oxidative and nitrative stress in human stomach associated with cagA+ Helicobacter pylori infection and inflammation. Dig Dis Sci 46:836-844, 2001
41. Kim H, Seo JY, Kim KH: Inhibition of lipid peroxidation, NF-kappaB activation and IL-8 production by rebamipide in Helicobacter pylori-stimulated gastric epithelial cells. Dig Dis Sci 45:621-628, 2000
42. Obst B, Wagner S, Sewing KF, Beil W: Helicobacter pylori causes DNA damage in gastric epithelial cells. Carcinogenesis 21:1111-1115, 2000
43. Khanzode SS, Khanzode SD, Dakhale GN: Serum and plasma concentration of oxidant and antioxidants in patients of Helicobacter pylori gastritis and its correlation with gastric cancer. Cancer Lett 195:27-31, 2003
44. Pignatelli B, Bancel B, Plummer M, Toyokuni S, Patricot LM, Ohshima H: Helicobacter pylori eradication attenuates oxidative stress in human gastric mucosa. Am J Gastroenterol 96:1758-1766, 2001
45. Noguchi K, Kato K, Moriya T, Suzuki T, Saito M, Kikuchi T, Yang J, Imatani A, Sekine H, Ohara S, Toyota T, Shimosegawa T, Sasano H: Analysis of cell damage in Helicobacter pylori-associated gastritis. Pathol Int 52:110-118, 2002
46. Zhang HM, Wakisaka N, Maeda O, Yamamoto T: Vitamin C inhibits the growth of a bacterial risk factor for gastric carcinoma: Helicobacter pylori. Cancer 80:1897-1903, 1997
47. Wang X, Willen R, Wadstrom T: Astaxanthin-rich algal meal and vitamin C inhibit Helicobacter pylori infection in BALB/cA mice. Antimicrob Agents Chemother 44:2452-2457, 2000 27
48. Gressier B, Cabanis A, Lebegue S, Brunet C, Dine T, Luyckx M, Cazin M, Cazin JC: Decrease of hypochlorous acid and hydroxyl radical generated by stimulated human neutrophils: Comparison in vitro of some thiol-containing drugs. Methods Find Exp Clin Pharmacol 16:9-13, 1994
49. Chu SH, Kim H, Seo JY, Lim JW, Mukaida N, Kim KH: Role of NF-kappaB and AP-1 on Helicobater pylori-induced IL-8 expression in AGS cells. Dig Dis Sci 48:257-265, 2003
50. Hayakawa M, Miyashita H, Sakamoto I, Kitagawa M, Tanaka H, Yasuda H, Karin M, Kikugawa K: Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J 22:3356-3366, 2003
51. Lee A: Animal models of gastroduodenal ulcer disease. Bailliere's Best Pract Res Clin Gastroenterol 14:75-96, 2000